Scientific Research

From Our Labs

When it comes to cancer, there’s power in a good partner

Combinations of drugs could hold the key to overcoming some of the biggest challenges in lung and other cancers.

CancerClinical ResearchInnovationOncologyScientific Research
Discovery

Stopping this coronavirus – and the next one

Inside the hunt for new antivirals to combat the current pandemic and to prepare for future ones.

Biomedical ResearchCOVID-19Drug DiscoveryNovartis Institutes for BioMedical ResearchScientific Research
Discovery

Solving the puzzle of immunotherapy

From an eccentric idea to a revolution in medicine – the history of immunotherapy and a peek into its future.

CancerInnovationScientific ResearchOncology
Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study

Basel, November 5, 2020 — Novartis, a leader in rheumatology and immuno-dermatology, today announced 12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized controlled trial, which demonstrated the significant treatment response of Cosentyx® (secukinumab) on synovitis (joint lining inflammation) in psoriatic arthritis (PsA)…

Scientific ResearchInnovationDrug Discovery
Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)

Basel, November 6, 2020 — Novartis today announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial evaluating the efficacy and safety of canakinumab in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)6. The ongoing trial failed to meet its primary endpoint…

Scientific ResearchDrug Discovery
Novartis builds on commitment to addressing need in neuropsychiatric disorders with Cadent Therapeutics acquisition

Basel, December 17, 2020 — Novartis has entered an agreement to acquire Cadent Therapeutics, a Cambridge, Massachusetts based neuroscience company. The acquisition adds two new clinical stage programs to the Novartis neuroscience portfolio, one for schizophrenia and the other for movement disorders. The agreement also includes a buyout of…

Scientific ResearchScientific DiscoveriesReimagine Medicine
Novartis global survey uncovers profound and often under-reported effects on sickle cell disease patients

Basel, December 9, 2019 — “We see sickle cell as a painful disease, but too often we don't translate how that pain affects the lives of our patients – can they go to school, can they work, can they enjoy their families? These are things many of us take for granted,” said Ifeyinwa Osunkwo, MD, MPH, Founder and Director, Sickle Cell Disease…

Tropical DiseasesScientific ResearchAfrica
Novartis and life sciences companies commit expertise and assets to the fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation

Basel, March 26, 2020 — Today, Novartis and a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture and delivery of vaccines, diagnostics, and treatments for COVID-19 in response to the pandemic. The industry brings a range of assets, resources, and expertise needed to identify…

Social CommitmentScientific ResearchReimagine Medicine
Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients

Basel, April 20, 2020 — Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalized patients with COVID-19 disease. The clinical trial drug supply will be provided by Sandoz,…

Social CommitmentScientific ResearchInfectious Diseases
Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis

Basel, June 17, 2020 — Novartis, a leader in rheumatology and immuno-dermatology, today announced that the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA), confirming Cosentyx efficacy in addressing the axial spondyloarthritis (axSpA) disease…

Scientific ResearchInnovationDrug DiscoveryAd Hoc
Discovery

Toward regrowing cartilage

Novartis researchers aim to improve the lives of patients with osteoarthritis.

Drug DiscoveryMusculoskeletal DiseasesScientific ResearchDrug Development
Discovery

The search for new options for patients with lung cancer

We’re working to bring the hope of advanced medicine to more patients.

CancerDrug DiscoveryInnovationOncologyScientific Research